(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 January 2015 (22.01.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/007520 A1

(51) **International Patent Classification**:
C07K 16/46 (2006.01) *C07K 19/00* (2006.01)

(21) **International Application Number**:
PCT/EP2014/063976

(22) **International Filing Date**:
1 July 2014 (01.07.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
13306045.9 19 July 2013 (19.07.2013) EP

(71) **Applicants**: **VIB VZW** [BE/BE]; Rijvisschestraat 120, B-9052 Gent (BE). **UNIVERSITEIT GENT** [BE/BE]; Sint-Pietersnieuwstraat 25, B-9000 Gent (BE). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE** [FR/FR]; 3, rue Michel-Ange, F-75794 Paris (FR). **UNIVERSITÉ MONTPELLIER 2** [FR/FR]; Place Eugène Bataillon, F-34095 Montpellier (FR). **CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER** [FR/FR]; 191 avenue du Doyen Gaston Giraud, F-34295 Montpellier (FR).

(72) **Inventors**: **TAVERNIER, Jan**; Bottelweg 2, B-9860 Balegem (BE). **ZABEAU, Lennart**; Dendermondsesteenweg 48B-501, B-9000 Gent (BE). **UZÉ, Gilles**; 4 Enclos Laffoux, 11 avenue de Castelnau, F-34090 Montpellier (FR). **PAUL, Franciane**; 174 rue Jean Thuile, F-34090 Montpellier (FR). **BORDAT, Yann**; Place Eugene Batallon, F-34095 Montpellier (FR). **GARCIN, Geneviève**; Rue de Tyr 89, Montpellier, 34090 (FR).

(74) **Common Representative**: **VIB VZW**; Rijvisschestraat 120, B-9052 Gent (BE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2015/007520 A1

(54) **Title**: TARGETING OF CYTOKINE ANTAGONISTS

(57) **Abstract**: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation- related disorders.